Drugs / Tegeo
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06427252 | May 2024 → May 2026 overdue | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05958849 | Aug 2023 → Jul 2024 | — | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tegeo | “4. Tegeo: Oral administration: 40 mg per dose for BSA \<1.25, 50 mg per dose for BSA 1.25 to 1.5, and 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle D1-D14, Q3W;” NCT06427252 ↗ |
| Route | Oral | “Tegeo: Oral administration” NCT06427252 ↗ |